October 23, 2022 New South Wales, Australia: Terminal cancer patients with refractory pain respond favorably to a proprietary cannabis spray containing equal ratios of plant-derived THC and CBD, according to data published in the journal PLOS One.
A team of Australian investigators assessed the safety and efficacy of a novel water-soluble oro-buccal nanoparticle spray containing 2.5 mgs of THC and 2.5 mgs of CBD in a cohort of patients with advanced cancer and intractable pain.
Read the ICBC synopsis here:
And the original medial study article here:
